Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinicopathological features of adult lymphoblastic lymphoma: a retrospective multicenter study from Türkiye.

Frontiers in oncology·2026
Same author

Clinical Associations of Osteoporosis in BCR::ABL1 Negative Myeloproliferative Neoplasms.

International journal of endocrinology·2026
Same author

Ruxolitinib-Treated Myeloproliferative Neoplasms: Real-World Infectious Outcomes and Preventive Practices from a Single Center.

Mediterranean journal of hematology and infectious diseases·2026
Same author

Tongue Uptake of 18F-FDG on PET/CT Mimicking Malignancy.

Clinical nuclear medicine·2026
Same author

Assessment of characteristics and treatment patterns of adult patients with acquired aplastic anemia in Turkiye (PLANE-TR).

Annals of hematology·2026
Same author

The Impact of Donor Hematological Parameters on Early Donor Complications: A Multicenter Donor Research Team Project.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2026

Related Experiment Video

Updated: Mar 7, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.7K

CD38 Expression and Variation as a Prognostic Factor Chronic Lymphocytic Leukemia.

Mesude Falay, Funda Ceran, Ahmet K Gunes

    Clinical Laboratory
    |February 7, 2017
    PubMed
    Summary

    A CD38 cutoff of 7% effectively identifies chronic lymphocytic leukemia patients needing early therapy and predicts low-risk cases. This prognostic marker aids in treatment decisions for CLL patients.

    More Related Videos

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
    09:01

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

    Published on: March 26, 2018

    14.8K
    Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
    09:02

    Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

    Published on: November 26, 2018

    22.6K

    Related Experiment Videos

    Last Updated: Mar 7, 2026

    HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
    11:29

    HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

    Published on: July 20, 2016

    11.7K
    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
    09:01

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

    Published on: March 26, 2018

    14.8K
    Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
    09:02

    Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

    Published on: November 26, 2018

    22.6K

    Area of Science:

    • Hematology
    • Oncology
    • Immunology

    Background:

    • Chronic lymphocytic leukemia (CLL) management requires accurate prognostic markers.
    • CD38 expression is a potential biomarker in CLL, but its optimal cutoff and variability need clarification.

    Purpose of the Study:

    • To establish a CD38 expression cutoff for identifying CLL patients requiring early therapy.
    • To predict low-risk CLL patients likely to experience rapid improvement.
    • To assess CD38 expression variability during the disease course.

    Main Methods:

    • Flow cytometry was used to measure CD38 and ZAP-70 expression in 124 CLL patients.
    • Time to initial therapy was calculated.
    • CD38 expression was re-evaluated in 50 patients during follow-up.

    Main Results:

    • A CD38 cutoff of 7% showed significant correlations with CLL prognostic parameters (p < 0.001).
    • Therapy initiation rates differed significantly between CD38+ and CD38- groups across cutoff levels (p < 0.001).
    • Multivariate analysis indicated STAGE, ZAP70, and CD38 (at 7% cutoff) significantly impacted survival.

    Conclusions:

    • A 7% CD38 cutoff, determined by standardized methods, is a significant prognostic marker for CLL.
    • Further cohort studies are needed to refine repeat measurement frequency and optimal cutoff levels for predicting CLL prognosis.